– Advancing Phase 2 and Phase 3 trials of obexelimab, a unique CD–19 x FcγRIIb inhibitor of B cell function–
–Topline results from Phase 2 Trial in [...] Read more »
– Advancing Phase 2 and Phase 3 trials of obexelimab, a unique CD–19 x FcγRIIb inhibitor of B cell function–
–Topline results from Phase 2 Trial in [...] Read more »
IRVINE, Califórnia, Feb. 05, 2025 (GLOBE NEWSWIRE) — A Read more »
IRVINE, Kalifornien, Feb. 05, 2025 (GLOBE NEWSWIRE) — Read more »
IRVINE, Californie, 05 févr. 2025 (GLOBE NEWSWIRE) — Read more »
IRVINE, Calif., Feb. 04, 2025 (GLOBE NEWSWIRE) — Read more »
SAN JOSE, Calif., Jan. 30, 2025 (GLOBE NEWSWIRE) — Zoom Communications, Inc. (NASDAQ: ZM) today announced it will release its financial results for the fourth quarter and full fiscal year 2025 on Monday, February 24, [...] Read more »
WALTHAM, Mass., Jan. 28, 2025 (GLOBE NEWSWIRE) — Zenas BioPharma, Inc. (“Zenas” or the “Company”) (Nasdaq: ZBIO), a clinical–stage global biopharmaceutical company committed to being a [...] Read more »
JERUSALEM, Jan. 27, 2025 (GLOBE NEWSWIRE) — Entera Bio Ltd. (NASDAQ: ENTX), (“Entera” or the “Company”) a leader in the development of orally delivered peptides and therapeutic proteins, [...] Read more »
INFORMATION RÉGLEMENTÉE
Publication relative à des notifications de transparence
Read more »
BRIDGEWATER, N.J., Jan. 07, 2025 (GLOBE NEWSWIRE) — Read more »
DUBAI, United Arab Emirates, Dec. 23, 2024 (GLOBE NEWSWIRE) — Swvl Holdings Corp (“Swvl” or the “Company”) (Nasdaq: SWVL), a leading technology provider of enterprise and government mobility [...] Read more »
REGULATED INFORMATION
Publication relating to transparency notifications
Read more »
INFORMATION RÉGLEMENTÉE
Publication relative à des notifications de transparence
Read more »